1. 2016
  2. Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort

    GUARD-C Study Group, Foster, G. R., Coppola, C., Derbala, M., Ferenci, P., Orlandini, A., Reddy, K. R., Tallarico, L., Shiffman, M. L., Ahlers, S., Bakalos, G. & Hassanein, T., 2016, In : PLoS ONE. 11, 3, 20 p., e0151703.

    Research output: Contribution to journalArticle

  3. Intensive Enteral Nutrition is Ineffective for Individuals with Severe Alcoholic Hepatitis Treated with Corticosteroids

    Moreno, C., Deltenre, P., Senterre, C., Louvet, A., Gustot, T., Bastens, B., Hittelet, A., Piquet, M-A., Laleman, W., Orlent, H., Lasser, L., Sersté, T., Starkel, P., De Koninck, X., Dastis, S. N., Delwaide, J., Colle, I., de Galocsy, C., Francque, S., Langlet, P. & 4 others, Putzeys, V., Reynaert, H., Degré, D. & Trépo, E., 2016, In : GASTROENTEROLOGY. 150, 4, p. 903 8 p.

    Research output: Contribution to journalArticle

  4. 2015
  5. Sofosbuvir in combination with simeprevir +/- ribavirin in genotype 4 hepatitis C patients with advanced fibrosis or cirrhosis: real-life experience from Belgium

    Reynaert, H., Dec 2015, In : Hepatology. 62, 1(suppl.), p. 140A 1 p.

    Research output: Contribution to journalMeeting abstract (Journal)

  6. The Hippo pathway effector YAP controls mouse hepatic stellate cell activation

    Mannaerts, I., Leite, S. B., Verhulst, S., Claerhout, S., Eysackers, N., Thoen, L. F. R., Hoorens, A., Reynaert, H., Halder, G. & van Grunsven, L. A., Sep 2015, In : Journal of Hepatology. 63, 3, p. 679-688 10 p.

    Research output: Contribution to journalArticle

  7. Distal intestinal obstruction in CF patients

    Maus, J., Mana, F., Reynaert, H. & Urbain, D., 30 Jun 2015, In : Acta Gastro-Enterologica Belgica. 78, 1, p. 49-52 4 p.

    Research output: Contribution to journalArticle

  8. Impact of intensive enteral nutrition in association with corticosteroids in the treatment of severe alcoholic hepatitis: a multicenter randomized controlled trial.

    Reynaert, H., 2015, In : Acta Gastro-Enterol Belg. 78, 1, p. A01 1 p.

    Research output: Contribution to journalMeeting abstract (Journal)

  9. Paritaprevir/Ritonavir, Ombitasvir and Dasabuvir with or without Ribavirin achieves 98,6% sustained virologic response in Belgian GT1 infected patients.

    Reynaert, H., 2015, In : Acta Gastro-Enterol Belg. 78, 1, p. A21 1 p.

    Research output: Contribution to journalMeeting abstract (Journal)

  10. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)

    Zeuzem, S., Flisiak, R., Vierling, J. M., Mazur, W., Mazzella, G., Thongsawat, S., Abdurakhmanov, D., Van Kính, N., Calistru, P., Heo, J., Stanciu, C., Gould, M., Makara, M., Hsu, S-J., Buggisch, P., Samuel, D., Mutimer, D., Nault, B., Merz, M., Bao, W. & 5 others, Griffel, L. H., Brass, C., Naoumov, N. V., ESSENTIAL II Study Group (with Hendrik Reynaert) & Reynaert, H., 2015, In : Alimentary Pharmacology & Therapeutics. 42, 7, p. 829-844 16 p.

    Research output: Contribution to journalArticle

  11. 2014
  12. SVR12 Rate of 95.7% in 209 HCV Genotype 1-Infected Null Responders Treated With ABT-450/r/Ombistarvir and Dasabuvir With or Without Ribavirin

    Reynaert, H., Oct 2014, In : Hepatology. 60, S1, p. 1133A

    Research output: Contribution to journalMeeting abstract (Journal)

Previous 1 2 3 4 5 6 7 8 ...26 Next

ID: 33804